Business Courses

Genomic Biomarkers, Companion Diagnostics (CDx), and Personalized Medicine 2012

This Business Course is being held in Boston, USA on the 20 April 2012 at 12:30-2:30pm

Price:

Enal Razvi Managing Director, Select Biosciences Inc

This course is designed to provide a comprehensive analysis of the current state of the companion diagnostics (CDx) field focusing on genomics-based biomarkers and their utility for stratified medicine.

Companion Diagnostics (CDx)	Genomic Biomarkers	Personalized Medicine (PDx)
Classes of cancer biomarkers Biological Significance and Proposed Role In Vivo Utility of Expression Patterns/Signatures as a Determinant for Physiological Processes as well as Disease/Pathological Situations Examples of Expression Patterns and Correlations
CDx Market Metrics Validated Biomarkers being Deployed for CD
ASRs and LDTs

This training course is ideally suited for researchers involved in investigations focusing on biomarker changes in biological and disease situations—both academic as well as from the industrial community. Indeed, there is currently extensive interest in the broader biomarker space as it impacts the development of companion diagnostics and personalized medicine. Also, this course is important for biotechnology, pharmaceutical, and related disciplines wherein industry participants—both technically focused as well as business focused—can get a solid understanding of the marketplace as well as receive the most up-to-date market data and associated materials for in-house research and business planning activities. Also, this course is recommended for investors as well as attorneys looking for a current technology and market review of this expanding field.

All attendees to this training course receive the electronic files of the presentation material on disk with full rights to use them in their internal R&D as well as business planning activities.

Training Course Specific Presentation Topics

• Companion Diagnostics Field
• Definition, Historical Perspective, Current Status
• Deployment of Genomic Biomarkers for Companion Diagnostics
• Currently-marketed Companion  Diagnostics and the Disease Classes they represent
• Breast Cancer
• Colon Cancer
• Other Cancer Classes
• Other Disease Classes such as Cardiovascular Disease
• Regulatory Landscape for Companion Diagnostics and Personalized Medicine
• ASRs and LDTs
• Market Opportunity and Metrics

For more information about this training course or for group registrations, please e-mail Kathy Gray at Kathy.Gray@SelectBiosciences.com